The University of Dayton Research Institute has won an Ohio Opioid Technology Challenge award for a program that will teach people with opioid addictions how to reduce their cravings by regaining control of their brains.
UDRI software engineer Kelly Cashion, who wrote the winning proposal and will lead the program, will develop and use a system of neurofeedback therapy designed to help people “recover control of their minds and bodies and accelerate the path to recovery,” Cashion said.
Cashion’s was one of five winning proposals — two from Ohio, two from Massachusetts and one from Utah — selected for funding by the Ohio Third Frontier from entries submitted from nine countries. The Ohio Opioid Technology Challenge was developed to help engender solutions to the nation’s growing opioid addiction crisis.
“When a person initially consumes opioids, the experience creates a sense of euphoria caused by a release of chemicals in the brain. The pathways in the brain that are part of that experience grow stronger — forging an addiction — while other pathways grow weaker,” she said. “Over time, use of the drugs stops creating positive feelings, and their absence creates painful symptoms of withdrawal, so that a person with an addiction needs to use the drugs just to achieve a sense of normalcy.
“Using neurofeedback, we’ll work with our volunteers to help them learn to regulate activity in the part of their brain associated with cravings and rewire some of those pathways, allowing them to reduce their cravings and experience a more ‘normal’ state even without opioids,” Cashion said.
Neurofeedback is a type of biofeedback where sensors are used in conjunction with a brainwave monitoring method, such as electroencephalography (EEG), to help the wearer see his or her brain’s electrical activity in real time.
In her program, Cashion will show volunteers a graphics display — which she likened to a simple video game — on a computer monitor. By giving the volunteers tasks that require a shift in focus or other interaction with the game, they will see which activities most positively impact the signals associated with cravings. After a series of training sessions, volunteers will have learned the tasks they will need to perform to reduce cravings, even without use of the technology.
Cashion said neurofeedback is showing promise in the treatment of nicotine addiction, depression, chronic pain, post-traumatic stress disorder and other physiological disorders. “We’ll build on that body of research and transfer known protocols to the domain of opioid addiction treatment,” she said.
Cashion said neurofeedback is not meant to be a substitute for, but a supplement to, current addiction therapies, which include medication-assisted treatment and behavioral counseling. “Current treatments are not always sufficient, and medication is not always sufficiently available because of the demand on treatment centers. Even when it is, some patients reject ‘step-down’ medications, such as methadone, because they view it as replacing one addiction with another. For those patients, neurofeedback can be another avenue for recovery.”
For patients who are transitioning to recovery with the use of medication, neurofeedback can provide additional insight into the changes enabled by the medication, Cashion added.
At the outset of her program, Cashion will work with health care professionals and other experts to help establish a baseline of neurological signals and identify which signals are associated with cravings. She’ll work with other researchers in UDRI’s Software Systems group to use mathematical algorithms to map the 2-dimensional baseline signal imagery to a 3-dimensional map of the brain. “From there we’ll be able to tell which parts of the brain the signals are coming from,” she said.
When she is ready to begin testing, Cashion will work with health care professionals and agencies which serve people with opioid addictions to help identify potential volunteers. As the program progresses, Cashion will continue to consult with technology experts within UDRI and external medical specialists to validate results and make adjustments as necessary.
“Ultimately our goal is to develop and demonstrate a neurofeedback system that uses off-the-shelf hardware along with software developed here at the University of Dayton Research Institute, then work with local medical technology companies to commercialize the product and make it available to treatment centers,” Cashion said.